Image courtesy of DivcoWest

With an additional 113,000-square-foot commitment, Bristol Myers Squibb has spoken for all of the office-lab space in DivcoWest’s 250 Water St. development at Cambridge Crossing.

The pharma giant originally leased 360,000 square feet at the speculative development last summer before committing to the latest expansion. The building is scheduled to be delivered in 2022.

Philips North America and Cerevel Therapeutics have leased all of the space at 22 Jacobs St., while French drugmaker Sanofi is occupying the 350 and 450 Water St. buildings.

That leaves approximately 600,000 square feet still available at Cambridge Crossing’s future 121 and 441 Morgan Ave. buildings. Construction of the 375,000-square-foot 441 Morgan Ave. will begin this spring, DivcoWest said.

DivcoWest acquired the long-planned development site on the Boston, Cambridge and Somerville line in 2015 for $291 million and launched a series of speculative buildings to tap into the life science industry’s space needs.

Cushman & Wakefield’s Bob Richards and Morford & Dodds Realty’s Bob Morford represented Bristol Myers Squibb in the latest lease transaction.